Bruinvels A T, Landwehrmeyer B, Waeber C, Palacios J M, Hoyer D
Sandoz Pharma Ltd., Basel, Switzerland.
Eur J Pharmacol. 1991 Sep 4;202(1):89-91. doi: 10.1016/0014-2999(91)90257-q.
The novel iodinated radioligand, serotonin-5-O-carboxymethyl-glycyl[125I] tyrosinamide, was used for binding studies with membranes of human substantia nigra. Evidence is provided for the existence in this tissue of a homogeneous population of recognition sites with the pharmacological profile of the 5-HT1D site.
新型碘化放射性配体血清素-5-O-羧甲基-甘氨酰[125I]酪氨酰胺用于与人黑质膜的结合研究。有证据表明该组织中存在具有5-HT1D位点药理学特征的均一识别位点群体。